REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for REGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REGN | Director; Chair | 85 | ["Nobel Prize for Physiology or Medicine in 1985","U.S. National Medal of Science in 1988","Distinguished Chair in Biomedical Sciences","Regental Professor of Molecular Genetics and Internal Medicine","Director of the Jonsson Center for Molecular Genetics"] | ["Corporate Governance and Compliance Committee","Technology Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 85 Director since: 1991 Board and Committee Membership 2025 Attendance Board of Directors: 14/15 Corporate Governance and Compliance Committee: 5/5 Technology Committee (Chair): 2/2 Career Highlights Distinguished Chair in Biomedical Sciences since 1989 and Regental Professor of Molecular Genetics and Internal Medicine and Director of the Jonsson Center for Molecular Genetics since 1985 at The University of Texas Southwestern Medical Center at Dallas Nobel Prize for Physiology or Medicine in 1985 (jointly with Dr. Goldstein) U.S. National Medal of Science in 1988 (jointly with Dr. Goldstein) Experience and Expertise Industry Experience Executive/Leadership Experience Science/Biotech Background Research/Academic Experience Scientific Society Memberships The National Academy of Sciences The National Academy of Medicine The Royal Society of London Dr. Brown s distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his significant industry experience gained through his service on the board of directors of the Company and the board of directors of a leading pharmaceutical company, led the board to conclude that Dr. Brown should serve as a director.